← Leaderboards
Carol Tacket
University Of Maryland Baltimore
$3,869,777
Attributed
$3,869,777
Total exposure
12
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $841.4K · FY2005–09$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$4,092,527 · 13
By mechanism
U19$1,864,935 · 1
N01$1,002,195 · 1
P20$445,500 · 2
R21$445,500 · 1
M01$334,397 · 8
Top collaborators
No co-investigators on record.
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Michelle Denise Shardell$10,123,189
- Michael Jeffrey Vinikoor$8,208,556
- Lijuan Yuan$3,888,254
- Jakub K Simon$808,670
- Osamah Jawaid Saeedi$3,009,831
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesClinical ResearchSerumResearch PersonnelInstitutionSourceResourcesFundingSalmonella TyphiSafetyGrantHuman SubjectComputer Retrieval Of Information On Scientific Projects DatabaseUnited States National Institutes Of HealthResponseImmune ResponseAntigensBaseMucosal ImmunityClinical TrialsProtocols DocumentationEpidemicImmunoglobulin AAttenuated
Grant awards (18)
CLINICAL TRIAL: PHASE I STUDY OF INTRANASAL NORWALK VLP VACCINE WITH ADJUVANT &$33,262
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PHASE I PRIME-BOOST STUDY OF VI POLYSACCHARIDE TYPHOID VACCINE A$4,377
M01 · FY2009 · RR · contact PI
Plant Based Microbicides and Vaccines to Prevent STIs$324,356
U19 · FY2008 · AI · contact PI
CLINICAL TRIAL: PHASE I PRIME-BOOST STUDY OF VI POLYSACCHARIDE TYPHOID VACCINE A$43,806
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PHASE I STUDY OF INTRANASAL NORWALK VLP VACCINE WITH ADJUVANT &$42,296
M01 · FY2008 · RR · contact PI
Plant Based Microbicides and Vaccines to Prevent STIs$365,386
U19 · FY2007 · AI · contact PI
PHASE I RANDOMIZED, DOUBLE-BLIND HETEROLOGOUS PRIME BOOST STUDY OF THE SAFETY &9$40,331
M01 · FY2007 · RR · contact PI
Plant Based Microbicides and Vaccines to Prevent STIs$391,888
U19 · FY2006 · AI · contact PI
Planning Grants for Institutional Clinical and Translational Science Awards$222,750
P20 · FY2006 · RR · contact PI
PLANNING GRANTS FOR INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARDS$222,750
P20 · FY2006 · RR · contact PI
PRIME-BOOST STUDY OF VI TYPHOID VACCINE AND ORAL TYPHOID VACCINE STRAIN CVD 909$3,962
M01 · FY2006 · RR · contact PI
Plant Based Microbicides and Vaccines to Prevent STIs$388,822
U19 · FY2005 · AI
CHOLERA 47000: USE OF IN VIVO EXPRESSION TECHNOLOGY TO IDENTIFY VIRULENCE FACTO$90,786
M01 · FY2005 · RR
Plant Based Microbicides and Vaccines to Prevent STIs$394,483
U19 · FY2004 · AI
Safety/Pharmacokinetics of caStx2 in Health$75,577
M01 · FY2004 · RR
MUCOSAL IMMUNITY AND ORAL TOLERANCE--INNATE IMMUNITY$222,750
R21 · FY2001 · AI
ENTERIC PATHOGENS - MUCOSAL RESEARCH UNIT$1,002,195
N01 · FY2000 · AI
MUCOSAL IMMUNITY AND ORAL TOLERANCE--INNATE IMMUNITY$222,750
R21 · FY2000 · AI